ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Osilodrostat

Also written as “LCI699” and “osilodrostat”.

Its studies are mostly in Hypertension · Cushing Syndrome · Adrenocortical Hyperfunction · Pituitary ACTH Hypersecretion · Essential Hypertension, led by 2 companies.

Drug pageOsilodrostat: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 17, 201413 company-led studies, 2 open or runningNext primary completion: Jul 21, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis100 open or runningphase 3since Jun 17, 2014Aug 5, 2008none ahead
RECORDATI GROUPits history only32 open or runningphase 4since Nov 19, 2025Jul 20, 2018Jul 21, 2027phase 2 · NCT03708900

Also a collaborator on its studies: Great Lakes Drug Development and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2008First study: phase 2 study in HyperaldosteronismFirst studyNCT00732771 · 12 enrolled · France
  2. Sep 23, 2008Phase 2 study in Essential HypertensionNCT00758524 · 628 enrolled · United States
  3. Jan 5, 20092 phase 2 studies in HypertensionNCT00817635, NCT00817414
  4. Apr 6, 2011Phase 2 study in Adrenocortical HyperfunctionNCT01331239 · 31 enrolled · United States, France, Italy and more
  5. Jun 17, 2014Phase 3 study in Adrenocortical HyperfunctionNCT02180217 · 137 enrolled · United States, Argentina, Austria and more
  6. Feb 23, 2015Phase 1 study in Hepatic ImpairmentNCT02372084 · 33 enrolled · United States
  7. Mar 20, 2015Phase 1 study in Renal InsufficiencyNCT02399202 · 15 enrolled · Bulgaria, Germany
  8. Jun 8, 2015Phase 2 study in Cushing SyndromeNCT02468193 · 9 enrolled · Japan
  9. Feb 27, 2016Phase 3 study in Pituitary ACTH HypersecretionNCT02697734 · 73 enrolled · United States, Belgium, Brazil and more

TargetBeta

“An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), ”NCIt, by rule
“Cytochrome P450 11B1 inhibitor”ChEMBL 37, by rule

Studies

All 10 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02697734Pituitary ACTH Hypersecretion · United States, Belgium, Brazil and more3CompletedJun 19, 201973
NCT02468193Cushing Syndrome · Japan2CompletedJun 7, 20189
NCT02399202Renal Insufficiency · Bulgaria, Germany1CompletedMar 21, 201615
NCT02372084Hepatic Impairment · United States1CompletedMay 19, 201633
NCT02180217Adrenocortical Hyperfunction · United States, Argentina, Austria and more3CompletedFeb 21, 2018137
NCT01331239Adrenocortical Hyperfunction · United States, France, Italy and more2CompletedOct 22, 201931
NCT00817635Hypertension · United States, Iceland2CompletedOct 13, 2009155
NCT00817414Hypertension · United States, Iceland2CompletedAug 12, 200963
NCT00758524Essential Hypertension · United States2CompletedJul 2, 2009628
NCT00732771Hyperaldosteronism · France2CompletedMay 200912

How it is read

Names in the registry

  • “LCI699”, 6 entries
  • “osilodrostat”, 5 entries
  • “Osilodrostat”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.